US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead
Executive Summary
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.
You may also be interested in...
Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill
Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry.
Medicare Could Save More than $80bn With Price Inflation Rebates – CBO Score of Senate Bill
Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.
Medicare Plan For Lowering Insulin Costs Takes Aim At Benefit Design Instead Of List Prices
The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.